 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 8 | 1/1 | 返回列表 |
| 查看: 2161 | 回復(fù): 7 | |||
sophia-yxh銅蟲 (正式寫手)
|
[求助]
這樣的審稿意見，我是修改再投還是換雜志呢？請大家評評
|
|
意見如下： Reviewer: 1 Comments to the Author In this paper, Yu et al. demonstrated that leonurine could protect PC12 cells from Na2S2O4- and glucose deprivation-induced apoptosis. The authors found that leonurine reduced Na2S2O4- and glucose deprivation-induced ROS production and restored the loss of mitochondria membrane potential. They also found that leonurine increased VEGF, Ras and Raf expression. The findings are of potential significance. Nevertheless, several issues preclude the acceptance of authors' work for publication in JPP at this stage. Major comments: 1. The manuscript is full of typo-grammatical mistakes. 2. The author did not explain why they chose PC12 cells as the cell model and Na2S2O4 as hypoxia-inducing agent. 3. The author did not explain why the protein levels of Ras and Raf were increased after leonurine treatment. VEGF is supposed to increase the activity but not the protein levels of Ras and Raf. 4. The author did not demonstrate that leonurine actually protected PC12 cells from apoptosis "through" VEGF/Ras/Raf/Erk pathway as described in the title. The authors should neutralize VEGF with antibody and determine if such manipulation could affect the protective effect of leonurine. Minor comments: 1. “OGD” is not a standard abbreviation and shall be fully spelled out in the title Reviewer: 2 Comments to the Author Manuscript Id: JPP-13-0647 Manuscript Title: Leonurine protects OGD-induced PC12 cells apoptosis through activation of VEGF/Ras/Raf/Erk signaling pathway. The current manuscript by Yu et al the showed the protective role of Leonurine against OGD induced PC12 cells apoptosis through activation of signaling pathway. However there are major concerns:- Authors mainly focussed to antiapoptotic activity of Leonurine. On the hand authors themselves mentioned in introduction section that leonurine, was reported to have cardioprotective and neuroprotective effect via increasing the antioxidantive and antiapoptotic effects. What difference this manuscript offer for readers? Authors used in vitro setup to show Leonurine effects and concluded that it might be applied as a potential therapeutic drug for ischemic injury treatment in abstract section. Is it justified to extrapolate in vitro preliminary results? Can leonurine cross BBB? Authors used vitamin E as positive control in some experiments but did not used for mechanistic studies though Vitamin E has reported to upregulate VEGF and other HIF-1 dependent genes in previous studies. Why authors used variable dose(s) of LN in different experiments. In Annexin why authors choosed only 25 uM and then again for caspase-3 author authors used 12.5 and 25 uM and for western blot 25 uM? Signalling pathway data has been not explained properly in result as well as discussion section which is supposed to be strength of manuscript. Minor comments:- References are not uniform, please check for format. Check for speling mistakes, typographical mistakes and please check for overall English. (Page 5:- 4th paragraph photoes spelling;Page 6 2nd paragraph Annexin ...kit was using to assess...Page 7 under result section 7th line was used is coming twice, 13th line showed no significant between..... Page 8 line 16; authors used only one concentration 25 uM but they mention concentration dependent manner? Date Sent: 28-Oct-2013 |
回復(fù)此樓» 猜你喜歡
一志愿中南化學(xué)337求調(diào)劑
已經(jīng)有4人回復(fù)
-
281求調(diào)劑（0805）
已經(jīng)有23人回復(fù)
-
265求調(diào)劑
已經(jīng)有9人回復(fù)
-
279分求調(diào)劑 一志愿211
已經(jīng)有10人回復(fù)
-
招收調(diào)劑碩士
已經(jīng)有12人回復(fù)
-
296求調(diào)劑
已經(jīng)有8人回復(fù)
-
招收博士1-2人
已經(jīng)有3人回復(fù)
-
085700資源與環(huán)境308求調(diào)劑
已經(jīng)有11人回復(fù)
-
274求調(diào)劑
已經(jīng)有8人回復(fù)
-
290求調(diào)劑
已經(jīng)有4人回復(fù)
» 本主題相關(guān)價值貼推薦，對您同樣有幫助:
- 給一個雜志審稿截止的時間超過了，怎么給編輯發(fā)郵件說對不起呢？
已經(jīng)有7人回復(fù)
- 請問大家，做MD方向的一篇小論文，有什么審稿較快，容易中的SCI雜志么？
已經(jīng)有16人回復(fù)
- 麻煩大家介紹個審稿周期快的關(guān)于植物生理、分子生物學(xué)方面的SCI雜志
已經(jīng)有6人回復(fù)
- OL投稿，審稿人超時一倍沒反應(yīng)，該提醒雜志嗎？
已經(jīng)有18人回復(fù)
- 請問如何成為雜志的審稿人？
已經(jīng)有35人回復(fù)
- 我這樣反駁雜志審稿人說我是抄襲，大家看怎么樣？
已經(jīng)有20人回復(fù)
- 某SCI雜志邀我做審稿人，要不要審稿？
已經(jīng)有46人回復(fù)
- 請大家推薦一個審稿周期較快的SCI雜志，關(guān)于農(nóng)業(yè)遙感方向
已經(jīng)有4人回復(fù)
- RSC的雜志，拒稿重投（reject and resubmssion）還需要回復(fù)審稿人意見嗎？
已經(jīng)有6人回復(fù)
- 論文審稿回來，3個審稿人，已經(jīng)修改提交了。不知道結(jié)果如何？大家評評
已經(jīng)有33人回復(fù)
- 求助：投了RSC雜志的EES，審稿結(jié)束后編輯直接給轉(zhuǎn)投到別的雜志了
已經(jīng)有4人回復(fù)
- 投英文雜志審稿意見居然是中文�。。�！
已經(jīng)有65人回復(fù)
- 請問Philosophical magazine letters雜志怎樣？
已經(jīng)有3人回復(fù)
- 請問大家知道elsevier出版的雜志measurement是否收審稿費和版面費�。�
已經(jīng)有11人回復(fù)
RXMCDM
版主 (文壇精英)
- 應(yīng)助: 401 (碩士)
- 貴賓: 1.908
- 金幣: 38947.6
- 散金: 4908
- 紅花: 88
- 沙發(fā): 4
- 帖子: 11453
- 在線: 1355.6小時
- 蟲號: 2739168
- 注冊: 2013-10-20
- 性別: GG
- 專業(yè): 一般管理理論與研究方法論
- 管轄: 論文翻譯
2樓2013-11-04 21:40:44
山海一色
木蟲 (著名寫手)
- 應(yīng)助: 211 (大學(xué)生)
- 金幣: 3220.7
- 散金: 341
- 紅花: 36
- 帖子: 1537
- 在線: 385.2小時
- 蟲號: 2625949
- 注冊: 2013-08-31
- 性別: GG
- 專業(yè): 控制論中的數(shù)學(xué)方法
3樓2013-11-04 21:47:11
sophia-yxh
銅蟲 (正式寫手)
- 應(yīng)助: 3 (幼兒園)
- 金幣: 329.2
- 散金: 488
- 紅花: 10
- 帖子: 528
- 在線: 245.2小時
- 蟲號: 1358919
- 注冊: 2011-08-02
- 性別: MM
- 專業(yè): 藥理學(xué)其他科學(xué)問題
4樓2013-11-04 21:49:11
山海一色
木蟲 (著名寫手)
- 應(yīng)助: 211 (大學(xué)生)
- 金幣: 3220.7
- 散金: 341
- 紅花: 36
- 帖子: 1537
- 在線: 385.2小時
- 蟲號: 2625949
- 注冊: 2013-08-31
- 性別: GG
- 專業(yè): 控制論中的數(shù)學(xué)方法
5樓2013-11-04 21:56:45
successfulsbl
木蟲 (職業(yè)作家)
- 應(yīng)助: 2006 (講師)
- 金幣: 15721.6
- 紅花: 45
- 帖子: 3388
- 在線: 851.9小時
- 蟲號: 286119
- 注冊: 2006-10-15
- 性別: GG
- 專業(yè): 有機分子功能材料化學(xué)
6樓2013-11-04 23:15:09
jinwei331
至尊木蟲 (文壇精英)
- 應(yīng)助: 3742 (副教授)
- 金幣: 28683.7
- 紅花: 73
- 沙發(fā): 1
- 帖子: 26959
- 在線: 1170.4小時
- 蟲號: 2085922
- 注冊: 2012-10-25
- 性別: GG
- 專業(yè): 機械測試?yán)碚撆c技術(shù)
7樓2013-11-05 00:00:53
aulsm
木蟲 (著名寫手)
博士
- 應(yīng)助: 755 (博后)
- 金幣: 7780.5
- 散金: 4671
- 紅花: 101
- 帖子: 2679
- 在線: 299.5小時
- 蟲號: 2421740
- 注冊: 2013-04-17
- 性別: GG
- 專業(yè): 計算機應(yīng)用技術(shù)
8樓2013-11-05 08:23:05
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 sophia-yxh 的主題更新
| 8 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 279分求調(diào)劑 一志愿211 +9 | chaojifeixia 2026-03-19 | 10/500 |
|
|---|---|---|---|---|
|
|
[考研] 085700資源與環(huán)境308求調(diào)劑 +10 | 墨墨漠 2026-03-18 | 11/550 |
|
|
[考研] 0703化學(xué)調(diào)劑 +10 | 妮妮ninicgb 2026-03-15 | 14/700 |
|
|
|
[考研] 307求調(diào)劑 +9 | 冷笙123 2026-03-17 | 9/450 |
|
|
|
[考博] 申博26年 +3 | 八6八68 2026-03-19 | 3/150 |
|
|
|
[考研] 本人考085602 化學(xué)工程 專碩 +17 | 不知道叫什么！ 2026-03-15 | 19/950 |
|
|
|
[考研] 一志愿西安交通大學(xué)材料工程專業(yè) 282分求調(diào)劑 +5 | 楓橋ZL 2026-03-18 | 7/350 |
|
|
|
[考研] 材料專業(yè)求調(diào)劑 +5 | hanamiko 2026-03-18 | 5/250 |
|
|
|
[考研] 299求調(diào)劑 +5 | △小透明* 2026-03-17 | 5/250 |
|
|
|
[考研] 278求調(diào)劑 +5 | 煙火先于春 2026-03-17 | 5/250 |
|
|
|
[碩博家園] 湖北工業(yè)大學(xué) 生命科學(xué)與健康學(xué)院-課題組招收2026級食品/生物方向碩士 +3 | 1喜春8 2026-03-17 | 5/250 |
|
|
|
[考研] 085601求調(diào)劑 +4 | Du.11 2026-03-16 | 4/200 |
|
|
|
[考研] 考研調(diào)劑 +3 | 淇ya_~ 2026-03-17 | 5/250 |
|
|
|
[考研] 0854控制工程 359求調(diào)劑 可跨專業(yè) +3 | 626776879 2026-03-14 | 9/450 |
|
|
|
[基金申請]
今年的國基金是打分制嗎？
 50+3
|
zhanghaozhu 2026-03-14 | 3/150 |
|
|
|
[考研] 070303 總分349求調(diào)劑 +3 | LJY9966 2026-03-15 | 5/250 |
|
|
|
[考研] 288求調(diào)劑 +4 | 奇點0314 2026-03-14 | 4/200 |
|
|
|
[考研] 本科南京大學(xué)一志愿川大藥學(xué)327 +3 | 麥田耕者 2026-03-14 | 3/150 |
|
|
|
[考研] 289求調(diào)劑 +4 | 這么名字咋樣 2026-03-14 | 6/300 |
|
|
|
[考研] 297一志愿上交085600求調(diào)劑 +5 | 指尖八千里 2026-03-14 | 5/250 |
|